| General Information |
| Business: |
(Incorporated in the Cayman Islands)
We are a newly formed blank check company. We intend to focus our search for a target company on the drug development and healthtech sectors. We will look for companies involved in drug development and commercialization , as well as those involved in diagnostic and healthcare technology and firms in the service sector. We may pursue a target affiliated with RA Capital.
Matthew Hammond, a partner on RA Capital Management’s investment team, is our CEO and a director.
(Note: Research Alliance Corp. III filed its S-1 for its SPAC IPO on March 24, 2026, and disclosed the terms of its stock-only SPAC: 5 million shares at $10.00 each to raise $50 million. Unlike most SPACs, Research Alliance III is not offering units consisting of a share of stock with either a warrant or a right attached.)
|
| Industry: |
BLANK CHECKS |
| Employees: |
0 |
| Founded: |
2026 |
| Contact Information |
| Address |
600 Fifth Avenue, 23rd Floor New York, NY 10020 Tel.: +1 (617) 778 2500New York, NY |
| Phone Number |
+1 (617) 778 2500 |
| Web Address |
|
| View Prospectus: |
Research Alliance III (Stock-Only SPAC) |
| Financial Information |
| Market Cap |
$74.67mil |
| Revenues |
$0 mil (last 12 months) |
| Net Income |
$0 mil (last 12 months) |
| IPO Profile |
| Symbol |
RACC |
| Exchange |
NASDAQ |
| Shares (millions): |
5.0 |
| Price range |
$10.00 - $10.00 |
| Est. $ Volume |
$50.0 mil |
| Manager / Joint Managers |
Leerink Partners |
| CO-Managers |
|
| Expected To Trade: |
|
|
Status:
|
TBA |
| Quiet Period Expiration Date: |
Available only to Subscribers |
| Lock-Up Period Expiration Date: |
Available only to Subscribers |
| SCOOP Rating |
Available only to Subscribers |
| Rating Change |
Available only to Subscribers |
